Form 4: Arcutis Biotherapeutics Executive Vice President Sells Shares Under 10b5-1 Trading Plan

Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Patrick Burnett, sold 3,871 shares of common stock at an average price of $13.5942 under a pre-arranged 10b5-1 trading plan.

Summary

• Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, sold 3,871 shares of common stock on May 8, 2025.
• The sale was executed under a 10b5-1 trading plan adopted on December 12, 2024, with a plan end date of February 27, 2026.
• The shares were sold at a weighted average price of $13.5942, with individual transaction prices ranging from $13.50 to $13.69.
• Following the transaction, Burnett directly owns 115,468 shares of Arcutis Biotherapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing an insider stock sale under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It's common for executives to use 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information. The impact on the stock price is usually minimal unless the sale is unusually large or coincides with other significant news.

Stakeholder Impact

• The sale of shares by an executive could have a minor negative impact on shareholder sentiment, but the effect is likely to be minimal given the existence of the 10b5-1 trading plan.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Patrick Burnett, Executive Vice President, Chief Medical Officer, Form 4, 10b5-1 trading plan, stock sale, insider trading